-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $56

Benzinga·02/26/2025 12:36:04
Listen to the news
HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and raises the price target from $7 to $56.